tbuckley/cabot-search huggingface dataset:
Identifying potential chemicals of concern in children's products in a regulatory context: a systematic evidence mapping approach
Authors: Gabrielle Rigutto, Elena Galkina, Logan V. Hayes, Simona Andreea Bălan
Journal: Environmental Health Perspectives (2025)

Children's vulnerability to chemical toxicant exposures demands strong consideration of the chemical composition of products designed for and marketed toward them. Inadequacies in health-protective legislation and lack of mandatory ingredient disclosure in most children's products have created significant gaps in protection and oversight. Scientific literature can provide insight into the chemical constituency of children's products that may be useful for prioritizing future regulatory efforts. We aimed to present a proof of concept for applying systematic evidence mapping methodology to identify which chemicals of potential concern have been reported in the scientific literature to be present in products marketed toward children, to inform future research and regulatory efforts. We conducted a broad, all-encompassing survey of the available literature from four databases to identify chemicals present in children's products. Using systematic evidence mapping methodologies, we constructed a database of children's products and their chemical constituents (termed "product-chemical combinations") based on a broad survey of current and relevant environmental health literature. Our study focused on chemicals present on the California Safer Consumer Products Program's Candidate Chemicals List, which includes chemicals with one or more known hazard traits. We then conducted an exploratory data analysis of product category and product-chemical combination frequencies to identify common chemicals in specific products. Our systematic evidence mapping identified 206 potentially hazardous chemicals in children's products, 170 of which were found in toys. In total, we found 1528 distinct product-chemical combinations; 582 product-chemical combinations included chemicals known to be hazardous or potentially hazardous. Ortho-phthalates in plastic toys, parabens in children's creams/lotions, and bisphenols in both baby bottles and teethers were the most frequently encountered product-chemical combinations of potential concern. The frequently reported presence of endocrine-disrupting chemicals in multiple types of children's products raises concerns for aggregate exposures and reveals gaps in regulatory protections for this sensitive subpopulation. Our reproducible and systematic evidence-based approach serves as a case study that can guide other prioritization efforts for transparent regulatory action aimed at improving the safety of chemicals in consumer products. https://doi.org/10.1289/EHP15394.
CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning
Authors: Kimberly McGregor, Michal Harel, Adam P. Dicker, Janakiraman Subramanian, Edgardo S. Santos, Itamar Sela, Yehonatan Elon, David R. Gandara
Journal: Journal of the National Comprehensive Cancer Network (2025)
Breast cancer gene-1 (<i>BRCA1</i>) potentiates maladaptive repair after kidney injury
Authors: Amrendra K. Ajay, Akinwande A. Akinfolarin, Cody C. Gifford, Venkata S. Sabbisetti, Joseph V. Bonventre
Journal: The Journal of Experimental Medicine (2025)

Maladaptive repair following kidney tubular injury leads to the development of interstitial fibrosis, a pathology common to chronic kidney diseases (CKD). Dysfunctional DNA damage response plays an important role in the progression of CKD. We found that BRCA1 expression was increased in the kidneys of patients with CKD and fibrotic kidneys of mice. Exon 11 deletion of Brca1 in proximal tubule cells (PTCs) of mice subjected to ischemic or nephrotoxic (aristolochic acid) injury resulted in a reduced number of senescent cells, as assessed by a decrease in phospho-histone H3, p16INK4a, RAD51 recruitment, G2/M cell cycle phase cells, GATA4, and senescence-associated β-galactosidase. There was less production of inflammatory profibrotic mediators and reduced kidney fibrosis. After cisplatin exposure in vitro, human PTCs with reduced BRCA1 had increased apoptosis, decreased RAD51 nuclear foci, and fewer cells in the G2/M cell cycle phase, with reduced IL-6 and sonic hedgehog production. Thus, BRCA1 regulates nonmalignant tissue responses to kidney injury, a role hitherto unrecognized.
Author Correction: LIMP-2 enhances cancer stem-like cell properties by promoting autophagy-induced GSK3β degradation in head and neck squamous cell carcinoma
Authors: Yuantong Liu, Shujin Li, Shuo Wang, Qichao Yang, Zhizhong Wu, Mengjie Zhang, Lei Chen, Zhijun Sun
Journal: International Journal of Oral Science (2025)
CRE25-048: A Rare Tumor Presentation in a Postpartum Female: Case Report of Malignant Peripheral Nerve Sheath Tumor Accompanying Neurofibromatosis Type I Diagnosis
Authors: Veronika Stefanishina, Sabrina Elliott, Sushant Remersu
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CRE25-048: A Rare Tumor Presentation in a Postpartum Female: Case Report of Malignant Peripheral Nerve Sheath Tumor Accompanying Neurofibromatosis Type I Diagnosis" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Suppression of BRAC1 facilitates kidney regeneration
Authors: Kaira A. Church, Xunian Zhou, Raghu Kalluri
Journal: The Journal of Experimental Medicine (2025)

Maladaptive repair following kidney injury leads to the development of kidney disease. In this issue of JEM, Ajay et al. (https://doi.org/10.1084/jem.20231107) uncover the role of breast cancer susceptibility gene 1 (BRCA1) in cell cycle arrest, DNA damage, and cell senescence, preventing maladaptive repair.
QIM25-232: Extracellular Vesicles Evade the Antiangiogenic Effect of Bevacizumab in Ovarian Cancer
Authors: Zhuoye Chen, Conghui Wang, Mingxia Xu, Tingjia Zhu, Yuehan Wang, Xiaodong Cheng, Xinyu Wang
Journal: Journal of the National Comprehensive Cancer Network (2025)
CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia
Authors: Anjali Advani, Olatoyosi Odenike, Deepa Jeyakumar, Raya Mawad, Olga Frankfurt, Jiuhong Zha, Jason G. Harb, Minh H. Dinh, Brian Jonas, Courtney D. DiNardo
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-058: First-in-Human, Multicenter Phase 1 Study of the Bromodomain 2 Inhibitor ABBV-744 in Relapsed/Refractory Acute Myeloid Leukemia" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma
Authors: Sandra Amponsah Frimpong, Valerie Shostrom, Robert Gregory Bociek, Matthew Lunning, Christopher D'Angelo, James Olen Armitage, Julie M. Vose
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-054: Long Term Follow Up of Patients Undergoing High Dose Chemotherapy and Autologous or Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BPI25-016: Real-World Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Insights From a Single Center in the Deep South
Authors: Todd William Mudd, Faris A. Abby, Darryl Outlaw, Mehmet Akce, Bassel El-Rayes, Midhun Malla, Qasim S. Hussaini, Garima Gupta
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-016: Real-World Outcomes of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Insights From a Single Center in the Deep South" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression
Authors: Natalie Johns, Alexander Rudich, Songzhu Zhao, Kenneth Chian, Po-Lan Su, Adam Khorasanchi, Jinesh Gheeya, Daniel Spakowicz, Lai Wei, Logan Roof, Asrar Alahmadi, Regan Memmott, Jacob Kaufman, Carolyn Presley, Kai He, Peter Shields, Christian Rolfo, David Carbone, Dwight Owen, Mingjia Li
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CGE25-110: Identification of an Elusive CBFA2T3-GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing
Authors: Yuna Lee, Sunwoo Yoon, Juyeon Lee, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Ji Hoon Phi, Ji Won Lee, Se Hoon Kim, Ryul Kim, Hyoung Jin Kang, June-Young Koh, Jung Yoon Choi
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients
Authors: Tianyuan Hu, Daniel Young, Atharv Sharma, Arrvind Sunder, Arindam Paul, Diganta Chowdhury
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-208: Clinical Outcomes for Medicaid Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample
Authors: Danielle C. Thor, Tony Elias, Ben Brik, Vineet Polineni
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-208: Clinical Outcomes for Medicaid Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample" published on 28 Mar 2025 by National Comprehensive Cancer Network.
PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model
Authors: Malgorzata Gil, Tao Yu, Meera Alderson, Kazuaki Takabe, Antonio D’Assoro, Shunqiang Li, Mateusz Opyrchal
Journal: Journal of the National Comprehensive Cancer Network (2025)

"PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model" published on 28 Mar 2025 by National Comprehensive Cancer Network.
PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology
Authors: Peter Schiemann, Michel Janicot, Gunther Wennemuth, Mykola Lyndin, Janine Moyer
Journal: Journal of the National Comprehensive Cancer Network (2025)

"PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors
Authors: Taimur Khalid, Hazem Aboaid, Daniel Thomas Jones, Jason Ta, Ramaditya Srinivasmurthy, Kenny Do, Kevin Nguyen, Karina Fama, Rishi Kumar Nanda, Sarah Aamer, Jo-Lawrence Bigcas, Kyaw Zin Thein
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors" published on 28 Mar 2025 by National Comprehensive Cancer Network.
QIM25-217: Quality of Data for Improvement of Prostate Cancer Services to Patients Treated at Tertiary Hospitals in Tanzania
Authors: Obadia Venance Nyongole, Castory Munishi, Nathanael Sirili, Deodatus Kakoko, Gasto Frumence, Daudi Simba, David Urassa, Bruno Sunguya
Journal: Journal of the National Comprehensive Cancer Network (2025)
HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab
Authors: Riccesha Hattin, Hazem Aboaid, Abbas Hussain, Savannah Schauer, Tal Schlesinger, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Kyaw Zin Thein
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab" published on 28 Mar 2025 by National Comprehensive Cancer Network.
EPR25-113: Mortality and DALY in Uterine Cancer Patients With High Body Mass Index: A Comparative Study of the United States and Global Data (1990–2021)
Authors: Charmi Bhanushali, Jayalekshmi Jayakumar, Vidhi Bhanushali, Sharanya Tripathi, Kalaivani Babu, Srinishant Rajarajan, Arya Mariam Roy
Journal: Journal of the National Comprehensive Cancer Network (2025)

"EPR25-113: Mortality and DALY in Uterine Cancer Patients With High Body Mass Index: A Comparative Study of the United States and Global Data (1990–2021)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy
Authors: Anuja V. Abhyankar, Myung-Ju Ahn, Grace K. Dy
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era
Authors: Andrew L. Pierce, Izel Okcu, Grzegorz Nowakowski, Seda Tolu, Jennifer Amengual, Che Ross, Jerome Graber, Alli Bock, Boyu Hu, Daniel Ermann
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era" published on 28 Mar 2025 by National Comprehensive Cancer Network.
QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-Time Using the Electronic Health Record (EHR)
Authors: Amye J. Tevaarwerk, Clare Gatten, Teshome Simret, Karthik Giridhar, Jamie Carroll, Pooja Advani, Sarayana Chumsri, Zhaohui Jin, Sumithra Mandrekar
Journal: Journal of the National Comprehensive Cancer Network (2025)

"QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-Time Using the Electronic Health Record (EHR)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
PCO25-211: HIF-1α Inhibitor ACF Synergizes With PARP Inhibitors Through the Exacerbation of Transcription-Replication Conflicts in Ovarian Cancer
Authors: Zhuoqun Lin, Jiaxin Gu, Dongxiao Hu, Tao Zhang, Ziyu Xing, Lingfang Wang, Xiaodong Cheng
Journal: Journal of the National Comprehensive Cancer Network (2025)

"PCO25-211: HIF-1α Inhibitor ACF Synergizes With PARP Inhibitors Through the Exacerbation of Transcription-Replication Conflicts in Ovarian Cancer" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CRE25-042: Advanced Fibrosis, TP53 Variants, and Erythroid Differentiation: Diagnostic Harbingers of ERCC6L2-Related Bone Marrow Failure Syndrome?
Authors: Sai Sudha Valisekka, Meghan E. Lindstrom, Olivia Jeannine Michel, Naveen Premnath, Craig E. Eckfeldt, Roy L. Kao
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CRE25-042: Advanced Fibrosis, TP53 Variants, and Erythroid Differentiation: Diagnostic Harbingers of ERCC6L2-Related Bone Marrow Failure Syndrome?" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)
Authors: Celine Hoyek, Angelo Pirozzi, Binbin Zheng, Naoko Lida, Ryne Ramaker, Seyi Abidoye, Cody Eslinger, Taro Shibuki, Christina S. Y. Wu, Mohamad Bassam Sonbol, Daniel H. Ahn, Mitesh Borad, Masafumi Ikeda, Yoshiaki Nakamura, Lorenza Rimassa, Takayuki Yoshino, John Strickler, Tanios Bekaii-Saab
Journal: Journal of the National Comprehensive Cancer Network (2025)

"CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
HSR25-192: Evaluation of Alternative Approaches to New Lesion Management and Measurable Disease Size Threshold on RANO-BM Response Assessment Following SRS for Brain Metastases
Authors: Tatiana Kashtanova, Andrew Keller, Naren Ramakrishna
Journal: Journal of the National Comprehensive Cancer Network (2025)

"HSR25-192: Evaluation of Alternative Approaches to New Lesion Management and Measurable Disease Size Threshold on RANO-BM Response Assessment Following SRS for Brain Metastases" published on 28 Mar 2025 by National Comprehensive Cancer Network.
QIM25-235: Exocrine Pancreatic Insufficiency (EPI) in Pancreatic Cancer Patients: Increasing Awareness and Screening
Authors: Adrianna Oraiqat, Nicole Nardella, Nathan Gilchrist, Sarah Goodchild, Dena Berhan, Laila Stancil, Pamela Hodul
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-011: A Case Study of Implementation of Clinical Decision Support Tools in the Expansion of Use of Bispecific T-Cell Engager (BiTE) Therapies in a Community Hospital System
Authors: Allison Lam, Angela Yencer, Milan Sheth, Jeanette Prado
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-011: A Case Study of Implementation of Clinical Decision Support Tools in the Expansion of Use of Bispecific T-Cell Engager (BiTE) Therapies in a Community Hospital System" published on 28 Mar 2025 by National Comprehensive Cancer Network.
BPI25-008: Improving Patient Access and Adherence: The Role of an Electronic Health Record (EHR)-Embedded Clinical Decision Support (CDS) Tool in Specialty Drug Management
Authors: Jonas M. Congelli, Anna Bolha, Rebecca Maniago, Mandi Vena, Marcello Ricottone, Maneet Kaur, Stephen Speicher
Journal: Journal of the National Comprehensive Cancer Network (2025)

"BPI25-008: Improving Patient Access and Adherence: The Role of an Electronic Health Record (EHR)-Embedded Clinical Decision Support (CDS) Tool in Specialty Drug Management" published on 28 Mar 2025 by National Comprehensive Cancer Network.
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy
Authors: Ramez Eskander, Jung-Yun Lee, Mansoor Mirza, Domenica Lorusso, Helen Mackay, Isabelle Ray-Coquard, Ana Oaknin, Antonio Gonzalez-Martin, Kosei Hasegawa, Bradley Corr, Xiaohua Wu, Alexandra Leary, Tianle Hu, Lea Dutta, Chinyere Okpara, Jodi McKenzie, Vicky Makker
Journal: Journal of the National Comprehensive Cancer Network (2025)

"TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.
TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ
Authors: Rachel Rabinovitch, Pat Whitworth, Pat Borgen, Anna Daily, Steve Shivers, Troy Bremer
Journal: Journal of the National Comprehensive Cancer Network (2025)

"TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ" published on 28 Mar 2025 by National Comprehensive Cancer Network.
CLO25-100: Improving Germline Testing in At-Risk Patients With Prostate Cancer
Authors: Juan Javier-DesLoges, Ana Flores Pimentel, Yu-Wei Chen, Yasoda Satpathy, James Michael Randall, Christopher Kane, Lisa Madlensky, Matthew Savage, Samuel Pena, Tyler Stewart, Aditya Bagrodia, Rana McKay
Journal: Journal of the National Comprehensive Cancer Network (2025)
BPI25-014: Pacritinib in Patients With Intermediate-1 Risk Myelofibrosis: Outcomes From Post-Hoc Analysis of Two Phase 3 Studies
Authors: Pankit Vachhani, Nikolai Podoltsev, Ashwin Kishtagari, Purvi Suthar, Michael Vredenburg, Karisse Roman-Torres, Aaron Gerds
Journal: Journal of the National Comprehensive Cancer Network (2025)
TIP25-241: Utilizing Augmented Reality as an Adjunct for Smoking Cessation: Trial in Progress
Authors: Skye O. Dougan, Helen C. Yates, Marilyn Horta, Karen O. Brandon, Madison Rivera, Halle R. Smith, Ursula Martinez, Steven K. Sutton, Damon J. Vidrine, Lee H. Ritterband, Kara P. Wiseman, Katrina A. Vickerman, Ranjita Poudel, Min-Jeong Yang, Thomas H. Brandon, Christine Vinci
Journal: Journal of the National Comprehensive Cancer Network (2025)
QIM25-218: Improving Quality Outcomes Through a Hospitalist-Driven Malignant Hematology Service
Authors: Grace Lee, Steven Benyahia, Mish Syed, Hardik Thakkar, Richard Reich, James Lochner, Leidy Isenalumhe, Timothy Hembree, Neha Verma, Enas Abdallah
Journal: Journal of the National Comprehensive Cancer Network (2025)